Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Maintenance Therapy
100%
Daclizumab
100%
Anti-CD25 Antibody
100%
Pancreas Transplantation
100%
Calcineurin Inhibitors
71%
Calcineurin Inhibitor Toxicity
57%
Nephrotoxicity
28%
Immunosuppression
14%
Randomized Trial
14%
Renal Function
14%
Renal Transplant Recipients
14%
Retrospective Analysis
14%
Control Subjects
14%
Infection Rate
14%
Loss Rate
14%
Patient Morbidity
14%
Intolerant
14%
Graft Success
14%
Patient Survival Rate
14%
Medicine and Dentistry
Pancreas Transplantation
100%
Calcineurin Inhibitor
100%
Maintenance Therapy
100%
Daclizumab
100%
Survival Rate
22%
Patient with Transplantation
22%
Nephrotoxicity
22%
Immunosuppressive Treatment
11%
Kidney Function
11%
Morbidity
11%
Graft Survival
11%
Infection Rate
11%
Nursing and Health Professions
Maintenance Therapy
100%
Pancreas Transplantation
100%
Calcineurin Inhibitor
100%
Daclizumab
100%
Survival Rate
22%
Nephrotoxicity
22%
Patient with Transplantation
22%
Graft Survival
11%
Immunosuppressive Treatment
11%
Morbidity
11%
Infection Rate
11%
Pharmacology, Toxicology and Pharmaceutical Science
Calcineurin Inhibitor
100%
Daclizumab
100%
Nephrotoxicity
22%
Survival Rate
22%
Morbidity
11%
Infection Rate
11%